Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- PMID: 25480827
- PMCID: PMC4294603
- DOI: 10.1634/theoncologist.2014-0187
Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Abstract
Background: Appropriate chemotherapy dosing for obese patients with malignant diseases is a significant challenge because limiting chemotherapy doses in these patients may negatively influence outcome. There is a paucity of information addressing high-dose chemotherapy in obese patients undergoing hematopoietic stem cell transplantation (HSCT).
Methods: The Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) designed an electronic survey to assess current practice of dose adjustment of chemotherapy in obese patients undergoing HSCT.
Results: A total of 56 EBMT centers from 27 countries responded to the online survey. Overall, 45 centers declared that they routinely adjust chemotherapy doses for obese patients (80.5%), and only 11 (19.5%) declared they do not adjust dose. Among the former group, most used body mass index as the parameter for defining obesity (28 centers, 62%). The method for determining the weight for chemotherapy calculation was actual body weight (ABW) in 16 centers, ideal body weight (IBW) in 10 centers, IBW plus 25% of the difference between IBW and ABW in 16 centers, and other methods for the rest. Among centers that used dose adjustment, 44% also capped the dose at 2 m(2) for a chemotherapy dose based on body surface area (BSA), whereas 56% did not cap. Interestingly, most of the centers (9 of 11) that did not adjust dose for weight also did not cap the BSA at 2 m(2).
Conclusion: This EBMT survey revealed large diversity among transplant centers regarding dose-adjustment practice for high-dose conditioning chemotherapy. Our next step is to analyze outcomes of transplantation according to dose-adjustment practice and, subsequently, to formulate a methodology for future prospective studies.
Keywords: Conditioning; Dose adjustment; Hematopoietic stem cell transplantation; Obesity.
©AlphaMed Press.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
Figures

Similar articles
-
Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.Biol Blood Marrow Transplant. 2018 Apr;24(4):687-693. doi: 10.1016/j.bbmt.2017.11.041. Epub 2017 Dec 7. Biol Blood Marrow Transplant. 2018. PMID: 29225163
-
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.Cancer Chemother Pharmacol. 2006 Jan;57(2):191-8. doi: 10.1007/s00280-005-0029-0. Epub 2005 Aug 25. Cancer Chemother Pharmacol. 2006. PMID: 16133536 Clinical Trial.
-
Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.Transplant Cell Ther. 2022 Dec;28(12):845.e1-845.e8. doi: 10.1016/j.jtct.2022.09.011. Epub 2022 Sep 24. Transplant Cell Ther. 2022. PMID: 36167308
-
[Vaccination].Klin Padiatr. 2001 Sep;213 Suppl 1:A77-83. doi: 10.1055/s-2001-17503. Klin Padiatr. 2001. PMID: 11577366 Review. German.
-
The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT.Bone Marrow Transplant. 2023 Sep;58(9):965-972. doi: 10.1038/s41409-023-02018-z. Epub 2023 Jul 5. Bone Marrow Transplant. 2023. PMID: 37407728 Review.
Cited by
-
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.Clin Transl Oncol. 2017 Jun;19(6):682-694. doi: 10.1007/s12094-016-1601-2. Epub 2017 Jan 10. Clin Transl Oncol. 2017. PMID: 28074400
-
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.ESMO Open. 2024 Feb;9(2):102383. doi: 10.1016/j.esmoop.2024.102383. Epub 2024 Feb 15. ESMO Open. 2024. PMID: 38364453 Free PMC article.
-
Higher Starting Dose of Ciclosporin Optimized Therapeutic Levels in Patients Receiving Phenytoin for Busulfan-induced Seizure Prophylaxis.Blood Cell Ther. 2021 Aug 25;4(3):58-64. doi: 10.31547/bct-2020-022. eCollection 2021 Aug 25. Blood Cell Ther. 2021. PMID: 36711059 Free PMC article.
References
-
- Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723–1727. - PubMed
-
- Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–570. - PubMed
-
- Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530–1538. - PubMed
-
- Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–1105. - PubMed
-
- Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous